65 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 receptor antagonists.

Cephalon
Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.

Cephalon
A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Cephalon
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

Cephalon
Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.

Cephalon
Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists.

Cephalon
Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.

Cephalon
Wake promoting agents: search for next generation modafinil, lessons learned: part III.

Cephalon
Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.

Cephalon
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c

Cephalon
Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H3 receptor antagonists.

Cephalon
Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity.

Cephalon
Amine-constrained pyridazinone histamine H3 receptor antagonists.

Cephalon
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.

Cephalon
Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.

Cephalon
Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.

Cephalon
TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone.

Cephalon
TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.

Cephalon
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.

Cephalon
Novel poly(ADP-ribose) polymerase-1 inhibitors.

Cephalon
D-amino acid containing, high-affinity inhibitors of recombinant human calpain I.

Cephalon
1,2-Benzothiazine 1,1-dioxide alpha-ketoamide analogues as potent calpain I inhibitors.

Cephalon
Proteasome inhibitors for cancer therapy.

Cephalon
Wake-promoting agents: search for next generation modafinil: part II.

Cephalon
Wake-promoting agents: search for next generation modafinil: part I.

Cephalon
Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H3 receptor antagonists with potent cognition enhancing activity.

Cephalon
Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity.

Cephalon
4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.

Cephalon
Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT6 receptor antagonist showing activity in rat social recognition test.

Cephalon
Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists.

Cephalon
Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,¿?¿.1¿?¿,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles.

Cephalon
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

Cephalon
Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.

Cephalon
Novel brain penetrant benzofuropiperidine 5-HT6 receptor antagonists.

Cephalon
Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.

Cephalon
Novel poly(ADP-ribose) polymerase-1 inhibitors.

Cephalon
4,5-dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists.

Cephalon
Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.

Cephalon
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.

Cephalon
Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.

Cephalon
Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity.

Cephalon
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.

Cephalon
Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.

Cephalon
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Cephalon
2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.

Cephalon
8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.

Cephalon
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.

Cephalon
1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.

Cephalon
Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.

Cephalon
Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.

Cephalon
Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Cephalon
Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.

Cephalon
Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on trkA tyrosine kinase activity.

Cephalon
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clin

Cephalon
Synthesis and kinase inhibitory activity of 3'-(S)-epi-K-252a.

Cephalon
1,2-Benzothiazine 1,1-dioxide P(2)-P(3) peptide mimetic aldehyde calpain I inhibitors.

Cephalon
Potent peptide alpha-ketohydroxamate inhibitors of recombinant human calpain I.

Cephalon
P2-achiral, P'-extended alpha-ketoamide inhibitors of calpain I.

Cephalon
P2-proline-derived inhibitors of calpain I.

Cephalon
Novel peptidyl phosphorus derivatives as inhibitors of human calpain I.

Cephalon
Fused pyrrolo[2,3-c]carbazol-6-ones: novel immunostimulants that enhance human interferon-gamma activity.

Cephalon
Potent inhibitors of proteasome.

Cephalon
5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

Genentech
Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors

Pfizer